<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04061278</url>
  </required_header>
  <id_info>
    <org_study_id>SAHZhejiangU-2019-009</org_study_id>
    <nct_id>NCT04061278</nct_id>
  </id_info>
  <brief_title>A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma Patients</brief_title>
  <official_title>A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study Comparing 4 Cycles of Neoadjuvant Chemotherapy Combined With Radiotherapy Versus 3cycles of Neoadjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy for the Treatment of N2-3 Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At the initial diagnosis of locally advanced nasopharyngeal carcinoma, a considerable
      proportion of patients have developed distant metastasis, forming subclinical lesions.
      Nowadays, with the advent of intensity modulated radiotherapy, the local-regional area is
      under well controlled. However, distant metastasis is still the main cause of failure in
      treatment of stage N2-3 nasopharyngeal carcinoma.The severe toxicity of synchronous
      chemotherapy and the dose intensity of single drug is not enough to effectively control
      existing subclinical lesions. Neoadjuvant chemotherapy with sufficient intensity (four
      cycles) can possible effectively kill subclinical lesions prior to the initiation of
      concurrent chemoradiotherapy, thereby reducing distant metastasis of stage N2-3
      nasopharyngeal carcinoma. Meanwhile, four cycles of chemotherapy have been shown to be well
      tolerated in other tumors. In conclusion, 4-cycle neoadjuvant chemotherapy in combination
      with radiotherapy is expected to further control the distant metastasis rate of N2-3
      nasopharyngeal carcinoma and improve the survival rate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-year overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>the duration between the date of diagnosed and date of patient death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5-year metastatic free survival</measure>
    <time_frame>5 years</time_frame>
    <description>the duration between the date of diagnosed and date of metastasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-year disease-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>the duration between the date of diagnosed and date of related disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year recurrence-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>the duration between the date of diagnosed and date of recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (incidence of grade 3/4 adverse reactions)</measure>
    <time_frame>5 years</time_frame>
    <description>treatment related toxic effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">246</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Neoadjuvant Chemotherapy</condition>
  <arm_group>
    <arm_group_label>4 Cycles of Neoadjuvant Chemotherapy With Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four cycles of neoadjuvant chemotherapy combined with radical radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3cycles of Neoadjuvant Chemotherapy With chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 cycles of Neoadjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy</intervention_name>
    <description>4 Cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy, instead of Concurrent Chemoradiotherapy</description>
    <arm_group_label>4 Cycles of Neoadjuvant Chemotherapy With Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy</intervention_name>
    <description>3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy, instead of definitive radiotherapy</description>
    <arm_group_label>3cycles of Neoadjuvant Chemotherapy With chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Non-keratinizing nasopharyngeal carcinoma diagnosed by pathology;

          2. According to the UICC/AJCC eighth edition staging criteria, clinical staging was
             T1-4N2 -3M0 (stage N2-3 nasopharyngeal carcinoma);

          3. Patients who have not received disease-related anti-tumor system therapy;

          4. Age 18~70 years;

          5. Perfect liver and kidney function: total bilirubin ≤1.5 times the upper limit of
             normal value (ULN); AST and ALT≤2.5 ULN; Alkaline phosphatase ≤2.5 ULN; Creatinine
             clearance rate ≥80 mL/min;

          6. Complete blood system function: neutrophil count (ANC) ≥2×109/L, platelet count
             ≥100×109/L and hemoglobin ≥9 g/dL;

          7. Cartesian score ≥70; or ECOG PS 0 or 1

          8. Prior to enrollment, the patients must undergo nasopharynx + neck MRI, chest + upper
             abdomen CT, ECT and other examinations of the whole body bone.

          9. Sign the informed consent.

        Exclusion Criteria:

          1. Patients with distant metastases were identified at the time of diagnosis;

          2. Patients with severe medical complications, severe organ (heart, lung) dysfunction, or
             neuropsychiatric disorders at the time of diagnosis;

          3. Previous cases of other malignancies;Complicated with other malignant tumors;Except
             for cured basal cell carcinoma of the skin or squamous cell carcinoma of the skin or
             carcinoma in situ of any other site;

          4. Use any other investigational drug or participate in another clinical trial with
             therapeutic intent within 3 months prior to enrollment;

          5. A woman who is pregnant or lactating;

          6. Known active HIV or HBV, HCV infection;

          7. Known to be allergic to drugs that may be used;

          8. The researchers did not consider participants to be eligible for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qichun Wei</last_name>
    <role>Study Chair</role>
    <affiliation>2nd Affiliated Hospital, School of Medicine, Zhejiang University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qichun Wei</last_name>
    <phone>0571-87783522</phone>
    <email>qichun_wei@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Xu</last_name>
    <phone>0571-87783522</phone>
    <email>shanyefengxu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benhua Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer prevention and treatment center, sun yat-sen university</name>
      <address>
        <city>Guandong</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuanhong Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital, college of medicinle, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Senxiang Yan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaozhong Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yongshi Jia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine, Zhejiang University, China</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310058</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zexin Chen</last_name>
      <phone>+86 0571 87783759</phone>
      <email>keyanlunli_zheer@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Xiaoshan Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>311200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guoping Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinhua Central Hospital</name>
      <address>
        <city>Jinhua</city>
        <state>Zhejiang</state>
        <zip>321000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wangyuan Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lishui City Central Hospital</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <zip>323000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dexi Du</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo Yinzhou People's Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo No.2 Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chuangzhou Rao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Quzhou</name>
      <address>
        <city>Quzhou</city>
        <state>Zhejiang</state>
        <zip>324000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huijuan He</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>May 10, 2020</last_update_submitted>
  <last_update_submitted_qc>May 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>Neoadjuvant Chemotherapy</keyword>
  <keyword>Concurrent Chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

